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The accidental discovery of the mouse polyoma virus nearly 50 years ago opened up an experimental system unique in
opportunities for investigating virus–host interactions leading to the development of tumors. Extensive studies of the virus
in tissue culture have provided a detailed understanding of its genetics and molecular biology. Knowledge of the virus as a
transforming agent in culture can now be tested in the animal where multiple cell types are targets for tumorigenic
conversion and where a variety of host factors, both immunological and nonimmunological, come into play. Studies in the
animal using well-characterized wild-type and mutant virus strains have led to some unexpected findings. Some of these run
counter to certain widely held beliefs in cancer biology. This minireview focuses on these surprising findings and the
challenges they raise. © 2001 Academic PressINTRODUCTION
Polyoma virus emerged in a surprising fashion in the
course of experiments aimed at demonstrating a viral
agent in mouse leukemia. Newborn mice injected with
cell-free extracts of leukemic tissues developed, instead
of leukemia, salivary gland carcinomas and a range of
other solid tumors (Eddy, 1969; Gross, 1983). The agent
responsible for this action was given the name “polyoma”
for its ability to induce multiple tumors. These have now
been shown to arise from more than a dozen different
cell types (Dawe et al., 1987b). While many of these
tumors remain microscopic, others grow rapidly, such
that the total tumor mass in an animal just 3 months of
age may comprise 25% or more of its total body weight.
Figure 1 illustrates the remarkable ability of this virus to
induce tumors in its natural host. Large tumors arising
from mammary gland, salivary gland, and thymus are
easily seen along with multiple tumors in the skin which
arise from hair follicles. In addition to these epithelial
tumors, tumors of mesenchymal origin, most commonly
renal sarcomas, osteosarcomas, hemangiomas, and
subcutaneous fibrosarcomas, are seen (Dawe et al.,
1987b). The virus has also been shown to induce other
pathologies including a runting syndrome (Bauer et al.,
1995; Bolen et al., 1985), a myeloproliferative disease
(Szomolanyi-Tsuda et al., 1994), polyarteritis (Dawe et al.,
1987a), as well as effects in enhancing autoimmune
disease (Tonietti and Oldstone, 1970), depending in part1 Address correspondence and reprint requests to author.
167on the particular virus strain and host genetic back-
grounds.
Following soon on its discovery, the virus was adapted
to cell culture and shown to induce neoplastic transfor-
mation of cells in vitro. Quantitative assays for virus
replication were developed based on plaque formation
on mouse cells. Assays for cell transformation utilized rat
or hamster fibroblasts which are nonpermissive for virus
replication and resistant to the lytic effects of the virus.
Figure 2 shows the transformation of established rat
embryo fibroblasts by polyoma based on focus formation
and growth in soft agar. Our knowledge of the molecular
biology of polyoma derives almost entirely from studies
of the virus in these cell culture systems (Cole, 1996).
Studies of oncogenic viruses as agents of cell trans-
formation have led to important discoveries with rele-
vance to human cancer. The ras, myc, fos, abl, and src
oncogenes and the p53, erbB2, and Wnt-APC tumor sup-
pressor gene pathways are a few prominent examples of
genes and pathways whose origins of discovery are
grounded in research on tumor viruses. These in vitro
systems nevertheless have obvious limitations as mod-
els for tumor induction. The cell culture systems used to
identify and characterize viral oncogenes utilize fibro-
blasts almost exclusively as target cells. Opportunities to
extend observations from tissue culture into the animal
have not always been available or pursued. Polyoma is
one of the few oncogenic viruses amenable to study both
in culture and in its natural host. The polyoma–mouse
system thus affords opportunities to test the relevance of
transforming functions in the context of tumor formation
in a variety of tissues and also to explore roles of the
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168 MINIREVIEWhost genetic background in determining susceptibility or
resistance to tumor development. In the nearly 50 years
since its discovery, research on polyoma virus has come
full circle—from the mouse to tissue culture and back to
the mouse.
ESSENTIAL FEATURES OF THE VIRUS
Three features of the virus contribute at different levels
to its ability to induce tumors so broadly and rapidly.
VP1, the outer capsid protein, binds to sialic acid as an
essential component of cell receptors (Chen and Ben-
jamin, 1997). Sialic acid in the appropriate linkage is
present as the terminal saccharide on many glycopro-
teins. There is no evidence for a unique receptor species
for polyoma (Bauer et al., 1999). Rather, it is assumed that
a heterogeneous class of sialoglycoproteins can serve
as primary receptors or attachment proteins for the virus.
Such proteins are abundantly and broadly expressed on
cell surfaces. The virus is thus able to establish a rapid
and widely disseminated infection in the newborn
mouse. This can be visualized by “whole mouse section”
hybridization as shown in Fig. 3. Microscopic examina-
tion of H & E sections immunostained for VP1 shows that
the virus can replicate in more than 40 different cell types
(Dawe et al., 1987b).
The virus has a versatile “multivalent” enhancer region
enabling it to be transcribed and to replicate in many
FIG. 1. Necropsy at 84 days of a C3H/BiDa mouse inoculated at birth
with the PTA strain of polyoma virus (see text).different cell types. The viral genome is a small double-
stranded circular DNA of 5.3 kb. A stretch of about 450 bpof noncoding DNA contains a replication origin flanked
by regulatory sequences that control expression from the
early and late viral promoters. This region is rich in
binding sites for cellular transcription factors. Perhaps 8
or 10 different factors—some of the “household” variety
such as members of the AP-1 family—have been shown
to bind in this region. A scan of the viral regulatory
sequences reveals as many as 30 possible binding sites
for known transcription factors. Some of these putative
sites may be used by the virus to replicate in various
target cells in vivo. Roles for different enhancer elements
in age-specific and tissue-specific virus replication as
well as in tumor induction have been demonstrated ex-
perimentally (Amalfitano et al., 1992; Campbell and Vil-
larreal, 1988; Freund et al., 1988a; Rochford et al.,
1990a,b, 1992; Rochford and Villarreal, 1991; Wirth et al.,
992).
Three T (“tumor”) antigens encoded by the virus inter-
ct with multiple cellular factors involved in growth sig-
aling pathways. Thus, while serving essential functions
n virus replication, the T antigens also have the potential
or altering cell growth controls. Table 1 summarizes
ome of the known interactions between the polyoma T
ntigens and cellular proteins. Middle T, the major trans-
orming protein, is an integral membrane protein that
inds and activates the tyrosine protein kinase pp60c-src
and other members of the c-src family. Middle T aloneFIG. 2. Transformation of F-111 rat embryo fibroblasts by polyoma
virus. (Top) Focus formation. (Bottom) Growth in soft agar.
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169MINIREVIEWcan transform some established fibroblasts (Treisman et
al., 1981), and regulated expression allows reversible
control over the transformed phenotype (Raptis et al.,
1985). Middle T serves as both an activator and substrate
of pp60c-src (Talmage et al., 1989). Phosphorylated middle
binds and triggers the action of at least three cellular
roteins involved in intracellular signaling and mitogen-
sis: phospatidylinositol 3-kinase (Auger et al., 1992;
almage et al., 1989; Whitman et al., 1985), phospho-
lipase C-g (Su et al., 1995), and Shc (Campbell et al.,
1994; Dilworth et al., 1994). Large T but not middle T is
able to override p53-induced arrest (Doherty and Freund,
1997, 1999). Large T binds and inactivates the retinoblas-
toma gene product pRb (Freund et al., 1992, 1994) as well
as the transcriptional coactivators p300/CBP (Cho et al.,
FIG. 3. Whole mouse section hybridization of a 10-day-old C3H/B
Hybridization with 35S-labeled viral DNA. (Bottom) H & E-stained sectio
TABLE 1
Functions of Polyoma Tumor Antigens
Large T Initiation of viral DNA synthesis
Transcriptional regulation
Binds retinoblastoma protein pRb and promotes
G1 3 S transition
Binds p300/CBP
Essential for immortalization in vitro
iddle T Binds, activates, and becomes a substrate for pp60c-src
Activation of SH2-containing signal transducers:
PI3-kinase, Shc, PLC-g
Small T Binds and inhibits PP2A
Activates MAP kinase pathway
Transactivates cyclin promoter(s)2001; Nemethova and Wintersberger, 1999). Small T has
a number of interesting properties most likely linked to
its ability to bind and inhibit the protein phosphatase
PP2A (Pallas et al., 1990). The role of the J domain
present in all three T antigens is important in mediating
certain T antigen functions including interactions with
other proteins (Campbell et al., 1995; Glenn and Eckhart,
1995).
Despite the extensive knowledge of T antigen func-
tions now available, there is reason to believe that some
important pieces of the puzzle may still be missing con-
cerning how polyoma replicates and induces tumors so
efficiently. This calls for new genetic screens or other
approaches designed to uncover possible additional
functions of the virus and cellular targets with which the
T antigens may interact.
SURPRISES AND CHALLENGES
Viral determinants
Not all “wild-type” virus strains are able to induce
tumors in the mouse. Large plaque or “high tumor”
strains induce tumors in essentially 100% of animals with
an average latency of 3–4 months. Small plaque or “low
tumor” strains induce few or frequently no tumors; more-
over, tumors which arise do so with a much longer
latency (6 months to a year) and are strictly of mesen-
use inoculated at birth with the PTA strain of polyoma virus. (Top)chymal and never epithelial origin (Dawe et al., 1987b).
Paradoxically, small plaque strains are generally found to
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170 MINIREVIEWhave an equal or sometimes higher efficiency of cell
transformation in vitro compared to large plaque strains.
The operative difference between “high” and “low”
tumor strains lies not in their transforming proteins
(Freund et al., 1988b) but in a single amino acid substi-
ution in the major capsid protein VP1 (Freund et al.,
991a). Results from multiple approaches—genetic, bio-
hemical, biological—point to the importance of this
ubstitution in allowing the virus to discriminate between
ifferent sialic acid linkages. This ability in turn governs
he extent and rapidity of virus spread in the animal
Bauer et al., 1999; Dubensky et al., 1991; Freund et al.,
991a,b, 1988). Results of X-ray crystallographic studies
ave shown that the residues involved form part of the
ialic acid binding pocket on the virus surface (Stehle et
l., 1994). Curiously, the high tumor strain is able to bind
nly single straight chain sialic acids while the low tumor
train binds branched as well as straight chain sialic
cids. The fact that small plaque strains, with broader
inding specificity, are restricted in their replication in
he mouse raises the possibility that these strains rec-
gnize and bind to a class of natural inhibitors or pseu-
oreceptors expressed in the host (Bauer et al., 1999;
tehle et al., 1994).
These findings raise several challenges focused on
he need for a better understanding of the earliest events
n viral infection. Given the broad spectrum of host cell
ypes the virus can infect and the presumably heteroge-
eous class of receptor molecules it utilizes, what path-
ay of uptake, cell entry, uncoating, and transport to the
ucleus does the virus follow, and are these the same in
ifferent cell types? What is the nature of the presumed
seudoreceptor that limits small plaque virus strains
rom replicating in the mouse?
Some T antigen functions are essential for transforma-
ion but are not required for tumor induction. This is best
llustrated by studies of a middle T mutant unable to bind
he Shc adaptor protein. This mutant, blocked in signal-
ng via the ras–raf–MAP kinase pathway, is defective in
ransforming cells in culture yet induces a broad spec-
rum of tumors in the mouse (Bronson et al., 1997). In
pecific target tissues, for example skin, the mutant in-
uces tumors that are several hundred times larger than
hose induced by the wild-type virus, while in other tis-
ues such as thymus, tumors induced by the mutant are
maller.
Results with this and other T antigen mutants indicate
hat differences in growth controls operating in various
arget cells affect the response to the virus and the
ikelihood of undergoing neoplastic transformation. The
rules” for transforming fibroblasts in culture are not en-
irely the same as those for inducing tumors in the intact
ost. Different transforming pathways initiated by the
irus may act in a largely redundant manner to induce
umors in some cell types and in a complementing or
ynergistic manner in other types. At least one pathway
p
ossential for transformation has a negative effect on
umor formation in a particular target cell (Bronson et al.,
997). Understanding the “hard-wiring” of growth controls
n each cell type will be necessary to understand its
esponse to the virus and the specific alterations re-
uired for tumorigenic conversion.
Two examples have been found of the converse rela-
ionship, i.e., where a mutant virus is able to transform in
ulture but is defective in inducing tumors. These relate
o mutations in large T which block replication but leave
he middle and small T functions unaffected (Cho et al.,
001; Li et al., manuscript submitted). These findings
mphasize the importance of virus replication and dis-
emination as a necessary prelude to tumor induction in
he mouse.
The ability of the virus to immortalize cells in culture is
ot essential to its ability to induce tumors. This is shown
y studies of large T mutants that are unable to bind the
etinoblastoma tumor suppressor protein pRb. These
utants are replication-defective in culture as a result of
eing unable to overcome G1 arrest. They are also de-
ective in their ability to immortalize primary cells. Re-
arkably, they remain fully able to replicate in the new-
orn mouse and they induce a tumor profile closely
esembling that induced by wild-type virus (Freund et al.,
992, 1994).
By what means these mutants overcome growth arrest
n the animal is unknown. These observations raise the
uestion of whether there may be still unrecognized
umor suppressor proteins or other cellular factors tar-
eted by the virus as essential steps in replication and
umor induction.
Polyoma appears to have no mechanism for directly
nactivating p53. In this regard, polyoma stands apart
rom its close relative SV40, from its more distant cousins
he highly oncogenic human papillomaviruses, and from
he oncogenic human adenoviruses. Each of these vi-
uses possesses a mechanism for nullifying p53 (re-
iewed in Howley et al., 1997). Evidence for a block in
ignaling between p19ARF and p53 in established poly-
ma transformed rat embryo fibroblasts has been re-
orted recently (Lomax and Fried, 2001). However, in the
ontext of tumor induction in the mouse, the virus ap-
ears to have no effective way of blocking p53 (Dey et al.,
000).
Genomic instability, frequently linked to p53 loss, is a
allmark of cancers in mice as well as in humans. If
olyoma is indeed unable to inactivate p53, how is it able
o induce tumors so efficiently? To what extent is poly-
ma tumor development driven by genomic instability? In
ontrast to spontaneous cancers in humans which
volve through a multihit process, polyoma tumors may
rise in a “single hit” from multiple oncogenic events
elivered through its T antigens. The development of
olyoma tumors may therefore depend little or not at all
n genomic instability. If this is so, the tumors should
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171MINIREVIEWremain strictly under T antigen control, unlike tumors
induced by SV40 large T for example (Ewald et al., 1996).
This prediction can be tested experimentally. On the
other hand, polyoma tumors, though generally not wildly
aneuploid, do show karyotypic changes (Sandros and
Stenman, 1990; unpublished observations). Are there
mechanisms still unknown by which the virus can either
block or bypass p53? Is there a novel pathway to
genomic instability in polyoma tumors that operates in-
dependently of p53 inactivation, and if so, what viral
functions and cellular targets are involved? New genetic
screens and sensitive cytogenetic approaches may help
to answer these questions.
A “tumor host range mutant selection procedure” has
been devised as a way to identify new cellular targets of
polyoma T antigens. Polyoma large T mutants that are
unable to bind pRb are in fact host range mutants, i.e.,
they are able to grow in culture only in cells with a
nonfunctional pRb pathway (Freund et al., 1994). This and
other observations suggest that screening for host range
mutants that are able to grow in tumor cells but not in
normal cells could provide a way to uncover new virus–
host protein interactions of importance to virus replica-
tion and tumorigenesis. Such a procedure has recently
been applied to polyoma. The procedure utilizes spon-
taneous or nonpolyoma tumor-derived cells as permis-
sive hosts and primary baby mouse kidney cells as the
nonpermissive hosts (Li et al., manuscript submitted).
Studies of such mutants coupled with yeast two-hybrid
screens have led to the identification of new cellular
targets of the large T protein. These interactions are
important in virus replication. The normal functions of
these cellular targets are of interest in terms of their
possible roles in regulating cell growth.
Host determinants
Not every strain of mouse is susceptible to tumor
induction by polyoma virus. More than 40 inbred strains
and some F1 hybrids have been tested. Responses were
found to vary from high susceptibility in which 100% of
animals come down with multiple tumors within a few
months to complete resistance in which no tumors de-
velop even after more than a year. Intermediate pheno-
types were also seen in which tumors develop at a
reduced frequency, or affecting some target tissues but
not others, or in which particular tumors have a high
propensity to metastasize (unpublished observations).
Determinants of general resistance. The most com-
mon form of resistance to polyoma tumors is based on
effective antitumor immunity. This immunological form of
resistance was first recognized in C57BL mice. These
normally resistant mice become susceptible following
neonatal thymectomy, irradiation, or treatment with “anti-
lymphocyte serum” (Allison and Law, 1968; Allison et al.,
1974; Law et al., 1967). Resistance to tumor development
1
gis not necessarily coupled with resistance to the virus
per se as shown by studies with the C57BR mouse.
These mice are susceptible as newborns to the virus but
develop no tumors. This is due to a CTL response me-
diated by CD81 Vb61 T cells which effectively eliminate
olyoma tumors but do not suppress the early acute
hase of virus replication in the newborn animal
Lukacher et al., 1995). The response is H-2Dk-restricted
and specific for an immunodominant peptide derived
from the middle T protein (Lukacher and Wilson, 1998).
As expected, C57BR mice become susceptible following
irradiation (Lukacher et al., 1995).
A distinctly different form of resistance, seen so far in
just a few strains, is directed to the virus and appears to
have a nonimmunological basis. Mice of these strains
develop few or no tumors even after irradiation (Carroll et
al., 1999). This “radiation-resistant” form of resistance is
manifested early in the infectious process, i.e., in block-
ing virus replication and spread. These mice also survive
infection by a highly virulent strain of polyoma that
causes early death from widespread lytic infection in
most other strains of mice (Bauer et al., 1995). These
observations are consistent with the view that this form
of resistance is directed to the virus as opposed to the
tumors. Interestingly, cells in culture derived from these
resistant mice are susceptible to infection by the virus.
These findings raise several interesting challenges.
One concerns the role of neonatal versus adult immunity
in controlling virus spread and tumor induction (Moser et
al., 2001). Understanding the mechanism of nonimmuno-
logical host resistance that effectively shuts down virus
replication in vivo is another.
Determinants of susceptibility. One form is dependent
on endogenous superantigen (Lukacher et al., 1995) and
the other is superantigen-independent (Velupillai et al.,
1999). The classical inbred mouse strains known to be
highly susceptible to polyoma owe their susceptibility to
their MHC type (H-2k) and to an endogenous mouse
mammary tumor provirus, Mtv-7. The Mtv-7 provirus en-
codes a superantigen which effectively deletes Vb61 T
ells, thus rendering these mice unable to mount an
ffective CTL response to polyoma tumors. Interestingly,
hile T cell deletion by an endogenous Mtv superanti-
en constitutes a susceptibility determinant to polyoma,
he same mechanism can function as a determinant of
esistance to the horizontal transmission of a homolo-
ous mouse mammary tumor virus (Golovkina et al.,
992).
A different basis of susceptibility has been identified in
ertain strains of “wild-derived” inbred mice. These
trains carry no detectable endogenous mouse mam-
ary tumor proviruses yet are as fully susceptible to
umor induction by polyoma as the classical inbreds with
uperantigen-mediated susceptibility (Velupillai et al.,
999). These mice possess the precursors required to
enerate polyoma-specific CTLs but develop a “type 2” T
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172 MINIREVIEWcell immunity in response to the virus and fail to sustain
a CTL response (Velupillai et al., manuscript in prepara-
ion).
Superantigen-dependent and -independent forms of
usceptibility are similar in their inability to mount or
ustain effective antitumor immune responses. Both
orms are transmitted in a dominant or codominant fash-
on in crosses with MHC-identical immunologically re-
istant mice, implying that both operate by mechanisms
hat actively interfere with generating effective tumor
mmunity. The genetic basis of superantigen-indepen-
ent susceptibility remains unknown but appears to be
ue to one or two dominantly acting genes (Velupilai et
al., 1999).
Some host factors affect tumor incidence or tumor
ehavior in a tissue-specific way. These phenotypes in-
clude specific resistance to the development of mam-
mary tumors in one strain and propensity for bone tu-
mors to metastasize in another (unpublished observa-
tions). The genetic and physiological bases for these
host responses are unknown.
The mouse has long been a subject of basic cancer
research. Mouse genetics is now aided by rapidly im-
proving methods for mapping, identifying, and manipu-
lating genes. These genetic methods coupled with phys-
iological studies will hopefully lead to an understanding
of the molecular mechanisms underlying these interest-
ing host phenotypes.
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